New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all day >>
05:46 EDTAXLAmerican Axle upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
05:42 EDTHBANHuntington Bancshares upgraded to Outperform at Keefe Bruyette
Keefe Brunette upgraded Huntington Bancshares to Outperform citing strong loan growth and an inexpensive relative valuation following the company's Q2 results. The firm raised its price target for shares to $11.50 from $10.
05:40 EDTSBNYSignature Bank reports Q2 EPS $1.48, consensus $1.43
Subscribe for More Information
05:39 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
Goldman Sachs upgraded Valspar to Conviction Buy from Neutral citing the valuation discount peers, the recovery in the U.S. housing market and momentum in the company's Australian business. The firm raised its price target for shares to $97 from $83.
05:36 EDTEDUNew Oriental Education announces $120M share repurchase program
On July 22, New Oriental's board authorized the repurchase of up to $120M of the company's shares during the period from July 28, 2014, through March 31, 2015.
05:36 EDTNEPNextEra Energy Partners initiated with an Outperform at BMO Capital
Subscribe for More Information
05:36 EDTTSETrinseo S.A. initiated with an Outperform at Wells Fargo
Subscribe for More Information
05:35 EDTEDUNew Oriental Education sees Q1 revenue $412M-$427M, consensus $463.36M
New Oriental Education commented, "This lower-than-normal projected revenue growth rate reflects the anticipated impact on the company's top-line performance of margin expansion initiatives in FY14, the transition to a new POP Kids program, changes in product mix and business seasonality, as well as certain macroeconomic factors. We are in the process of reducing our previous learning center opening plan of 10-12 per quarter in light of the slower than expected revenue growth outlook for our Q1."
05:35 EDTMTDRMatador downgraded to Hold from Buy at Stifel
Subscribe for More Information
05:34 EDTTSETrinseo S.A. initiated with a Buy at Jefferies
Subscribe for More Information
05:34 EDTSTISunTrust downgraded to Equal-Weight from Overweight at Evercore
Evercore downgraded SunTrust to Equal-Weight citing the recent outperformance of shares and net interest margin headwinds. The firm lowered its price target for shares to $40 from $42.
05:32 EDTEDUNew Oriental Education reports Q4 EPS 30c, consensus 24c
Subscribe for More Information
05:32 EDTNEPNextEra Energy Partners initiated with a Hold at KeyBanc
Subscribe for More Information
05:32 EDTCDNSCadence Design downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Cadence Design to Neutral following the company's Q2 results citing valuation and gross margin pressure in the second half of 2014. The firm has an $18 price target for shares.
05:30 EDTDLRDigital Realty upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
05:29 EDTFIVEFive Below upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
05:27 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
05:26 EDTTSETrinseo S.A. initiated with a Buy at Goldman
Subscribe for More Information
05:25 EDTHASHasbro upgraded to Overweight from Equal Weight at Barclays
Subscribe for More Information
05:25 EDTADX, AZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use